5-氨基-6-氯-3-吡啶羧酸甲酯 | 211915-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氨基-6-氯-3-吡啶羧酸甲酯
• 中文别名: 5 - 氨基-6 - 氯-3 - 吡啶羧酸甲酯
• 英文名称: methyl 5-amino-6-chloronicotinate
• 英文别名: methyl 5-amino-6-chloropyridine-3-carboxylate
• CAS: 211915-96-7
• 化学式: C₇H₇ClN₂O₂
• mdl: MFCD02180841
• 分子量: 186.598
• InChiKey: BENHZYFIGMDHEB-UHFFFAOYSA-N

物化性质

• 沸点：
  328.2±37.0 °C(Predicted)
• 密度：
  1.384±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在2-8°C的环境中，避免光照，并保持在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-amino-6-chloropyridine-3-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-amino-6-chloropyridine-3-carboxylate
CAS number: 211915-96-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7ClN2O2
Molecular weight: 186.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-6-氯-3-吡啶羧酸甲酯 在 吡啶 、 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙腈 为溶剂， 反应 69.0h， 生成 methyl 5-(m-tolylsulfonyl)-5,6-dihydro-1,5-naphthyridine-3-carboxylate
  参考文献：
  名称：

  [EN] TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  [FR] TÉTRAHYDRONAPHTYRIDINE ET COMPOSÉS BICYCLIQUES APPARENTÉS POUR L'INHIBITION DE L'ACTIVITÉ RORGAMMA ET LE TRAITEMENT D'UNE MALADIE

  摘要：

  公开号：

  WO2013169704A3
• 作为产物：
  描述：

  6-氯-5-硝基烟酸甲酯 在 铁粉 、 溶剂黄146 作用下， 以97 %的产率得到5-氨基-6-氯-3-吡啶羧酸甲酯
  参考文献：
  名称：

  一种PD-1/PD-L1抑制剂及其制备方法和用途

  摘要：

  本发明提供了一种作为PD‑L1抑制剂的化合物及其制备方法和用途。本发明还公开了本发明化合物或其药物组合物在制备药物中的用途，该药物用于预防和治疗与PD‑L1相关的疾病。

  公开号：

  CN115611924A

文献信息

• 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20170166552A1

  公开（公告）日：2017-06-15

  The present invention provides a 1,4-disubstituted imidazole derivative of formula (1′) wherein ring Q 1 is optionally-substituted C 6-10 aryl group, etc.; R 1 and R 2 are independently hydrogen atom, etc.; W 1 is optionally-substituted C 1-4 alkylene group; W 2 is —NR 3a C(O)— wherein R 3a is hydrogen atom or C 1-6 alkyl group, etc.; ring Q 2 is 5- to 10-membered heteroaryl group, etc.; W 3 is optionally-substituted C 1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R 4 is independently halogen atom, optionally-substituted C 1-6 alkyl group, etc.; R 5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.

  本发明提供了一种公式（1'）的1,4-二取代咪唑衍生物，其中环Q1是可选取代的C6-10芳基等；R1和R2分别是氢原子等；W1是可选取代的C1-4烷基烯基；W2是—NR3aC(O)—，其中R3a是氢原子或C1-6烷基等；环Q2是5-到10-成员杂芳基等；W3是可选取代的C1-4烷基烯基等；n为1, 2, 3, 4或5；R4是独立的卤原子、可选取代的C1-6烷基等；R5是羟基等；以及其药理学上可接受的盐，对癌细胞的球形形成能力具有强大的抑制作用，并且作为口服抗肿瘤药剂是有用的。
• [EN] TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE<br/>[FR] TÉTRAHYDRONAPHTYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE ET COMPOSÉS BICYCLIQUES APPARENTÉS POUR L'INHIBITION DE L'ACTIVITÉ DE RORGAMMA ET LE TRAITEMENT DE MALADIE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095795A1

  公开（公告）日：2015-06-25

  The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

  这项发明提供了公式（I）的某些双环杂环化合物或其药学上可接受的盐，其中X1、X2、R1、R2、R3、R4和Cy如本文所定义。该发明还提供了包括公式（I）的这种化合物或其药学上可接受的盐的药物组合物，以及使用公式（I）的这种化合物或其药学上可接受的盐或包含相同的药物组合物治疗由RORgammaT介导的疾病或症状的方法。
• Disubstituted bicyclic heterocycles, the preparations and the use
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06087380A1

  公开（公告）日：2000-07-11

  New disubstituted bicyclic heterocycles of general formula R.sub.a --A--Het--B--Ar--E (I) Compounds of the above general formula I, wherein E denotes an R.sub.b NH--C(.dbd.NH)-- group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E denotes a cyano group, are valuable intermediates for preparing the other compounds of general formula I. Exemplary compounds of formula I are: (a) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide, (b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, (c) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl- carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, and (d) 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimid azol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl) amide.

  新的二取代杂环化合物的一般公式为R.sub.a --A--Het--B--Ar--E（I）。上述一般公式I的化合物中，E代表一个R.sub.b NH--C(.dbd.NH)--基团，具有有价值的药理特性，特别是抑制凝血酶的作用和延长凝血酶时间的作用，其中E代表氰基的化合物是制备一般公式I其他化合物的有价值中间体。公式I的示例化合物包括：（a）1-甲基-2-[N-(4-氨基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-苯基-N-(2-羟基羰基乙基)-酰胺，（b）1-甲基-2-[N-(4-氨基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基羰基甲基)-酰胺，（c）1-甲基-2-[N-(4-氨基-2-甲氧基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基羰基甲基)-酰胺，和（d）1-甲基-2-[N-[4-(N-己氧羰胺基)苯基]氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(2-乙氧羰基乙基)酰胺。
• [EN] THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS<br/>[FR] COMPOSÉS THIAZOLOPYRIDINES DE MODULATION DES SIRTUINES
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2010071853A1

  公开（公告）日：2010-06-24

  Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了结构式（Ia）的新型sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和紊乱，包括与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。还提供了包含sirtuin调节化合物与另一治疗剂组合的组合物。
• [DE] DISUBSTITUIERTE BICYCLISCHE HETEROCYCLEN, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] DISUBSTITUTED BICYCLIC HETEROCYCLES, THEIR PRODUCTION AND USE AS MEDICAMENTS<br/>[FR] HETEROCYCLES BICYCLIQUES DISUBSTITUES, PRODUCTION ET UTILISATION COMME MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM PHARMA KG

  公开号：WO1998037075A1

  公开（公告）日：1998-08-27

  (DE) Die vorliegenden Erfindung betrifft neue disubstituierte bicyclische Heterocyclen der allgemeinen Formel (I): Ra-A-Het-B-Ar-E, in der A, B, Ar, Het und Ra wie im Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere, deren Gemische und deren Salze, welche wertvolle Eigenschaften aufweisen. So stellen die Verbindungen der obigen allgemeinen Formel (I), in denen E eine Cyanogruppe darstellt, wertvolle Zwischenprodukte zur Herstellung der übrigen Verbindungen der allgemeinen Formel (I) dar, und die Verbindungen der obigen allgemeinen Formel (I), in denen E eine RbNH-C(=NH)-Gruppe darstellt, weisen wertvolle pharmakologische Eigenschaften auf, insbesondere eine Thrombin-hemmende und die Thrombinzeit verlängernde Wirkung.(EN) The invention relates to new disubstituted bicyclic heterocycles of the general formula (I): Ra-A-Het-B-Ar-E, in which A, B, Ar, Het and Ra are defined as in claim 1. The invention also relates to their tautomers, their stereoisomers, their mixtures, and their salts, which have valuable properties. The compounds of the above general formula (I), in which E is a cyano group, thus represent valuable intermediate products for the production of the other compounds of the general formula (I). Furthermore, the compounds of the above general formula (I), in which E stands for a RbNH-C(=NH)-group, have valuable pharmacological properties, in particular in inhibiting thrombin and prolonging thrombin time.(FR) L'invention concerne de nouveaux hétérocycles bicycliques disubstitués de la formule générale (I): Ra-A-Het-B-Ar-E, où A, B, Ar, Het et Ra sont décrits dans la revendication 1. Elle concerne aussi leurs tautomères, stéréo-isomères, mélanges et sels, qui ont des propriétés utiles. Les composés de la formule générale ci-dessus (I), où E est un groupe cyano, représentent donc des produits intermédiaires utiles pour la production des autres composés de la formule générale (I). Par ailleurs, les composés de la formule générale (I), où E représente un groupe RbNH-C(=NH), ont de précieuses vertus pharmaceutiques et peuvent notamment inhiber la thrombine et prolonger le temps de thrombine.

  本发明涉及新的二取代的双环杂环化合物，其通式为（I）：Ra-A-Het-B-Ar-E，在该式中，A、B、Ar、Het和Ra的定义如权利要求1中所述。本发明还涉及它们的互变异构体、立体异构体、混合物和盐，具有有价值的性质。因此，上述通式（I）中E为氰基的化合物代表制备通式（I）中其他化合物的有价值的中间体。此外，上述通式（I）中E代表RbNH-C（=NH）基团的化合物具有有价值的药理学性质，特别是抑制凝血酶和延长凝血酶时间的作用。